Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maximal Use Trial of Ruxolitinib Cream in Prurigo Nodularis
NCT06213831Phase 1Completed
- Sponsor
- Incyte
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib cream in prurigo nodularis (PN), sponsored by Incyte. Primary endpoints: Number of participants with Treatment-emergent Adverse Events at 16 weeks and Number of participants with TEAEs leading to dose interruption or discontinuation at 16 weeks. Started Feb 2024; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06213831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213831.